NAZLI ERDOĞAR

Dr. NAZLI ERDOĞAR

Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
NENAZLI ERDOĞAR
NAZLI ERDOĞAR
AIAlper B. İsKit
Alper B. İsKit
HEHakan Eroglu
Hakan Eroglu
MSMustafa F. Sargon
Mustafa F. Sargon
NMN. Aydın Mungan
N. Aydın Mungan
and Erem Bilensoyand Erem Bilensoy
and Erem Bilensoy

13 January 2021 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
NENAZLI ERDOĞAR
NAZLI ERDOĞAR
SASafiye Akkın
Safiye Akkın
TNThorbjorn T. Nielsen
Thorbjorn T. Nielsen
EÖEsin Özçelebi
Esin Özçelebi
BEBatuhan Erdoğdu
Batuhan Erdoğdu
EBErem Bilensoy
Erem Bilensoy

11 December 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
NENAZLI ERDOĞAR
NAZLI ERDOĞAR
BGBetül Gür
Betül Gür
DÖDilara Örgül
Dilara Örgül
Topical and transdermal drug delivery faces continuous challenges, primarily due to the formidable barrier function of the stratum corneum (SC), which limits the bioavailability of therapeutics. Nanotechnology-based drug delivery systems (NDDS) have emerged as powerful strategies to overcome these limitations, offering improved drug permeation, sustained release, and enhanced solubility for hydrophobic compounds. This review provides a critical and concise analysis of the latest advancements in NDDS, specifically those employed for both dermal (localized) and transdermal (systemic) delivery. Key nanosystems, including lipid-based, polymeric nanoparticles, vesicular structures, nanoemulsions, nanofibers, dendrimers and micelles are explored, highlighting how their unique physicochemical properties facilitate optimized drug performance. Crucially, the design strategies that selectively target the dermis versus those engineered for transdermal penetration are compared and contrasted. Furthermore, the often-overlooked clinical aspects, including the current understanding of the in vivo fate, biocompatibility, and safety profile of these nanocarriers within the skin layers, are addressed. This comprehensive evaluation provides a foundation for future development of safer and more effective nanomedicines for cutaneous applications.

8 November 2019 in Journal of Inclusion Phenomena and Macrocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
NENAZLI ERDOĞAR
NAZLI ERDOĞAR
ENEmirhan Nemutlu
Emirhan Nemutlu
AIAlper B. İsKit
Alper B. İsKit
SKS. Cihan Kara
S. Cihan Kara
ZTZeynep Şafak Teksin
Zeynep Şafak Teksin
and Erem Bilensoyand Erem Bilensoy
and Erem Bilensoy

28 October 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NENAZLI ERDOĞAR
NAZLI ERDOĞAR
Erlotinib (ERL) is a tyrosine kinase inhibitor that has been used in the treatment of metastatic non-small cell lung cancer (NSCLC). However, its low aqueous solubility limits its absorption and oral bioavailability. To overcome these pharmacokinetic drawbacks, complexation of ERL can be applied. The aim of this study was to develop and characterize an oral tablet formulation containing ERL: Randomly methylated-β-cyclodextrin (RAMEB-CD) inclusion complex to enhance solubility and oral bioavailability of ERL. An inclusion complex was prepared with RAMEB-CD using co-lyophilization technique. Structural characterization was performed using X-ray diffractometry and fourier-transform infrared spectroscopy. Tablet formulation of ERL: RAMEB-CD inclusion complex were prepared using direct compression technique. Tablet characteristics like hardness, diameter, thickness, friability, weight variability, disintegration and dissolution were evaluated. Flow properties of the powder were also determined. Characterization studies suggested that stable complexes between ERL and RAMEB-CD were obtained with co-lyophilization method. Tablet formulation using inclusion complex of ERL and RAMEB-CD with drug dose equivalent to 25 mg was successfully prepared using direct compression technique. Physical properties of the powder mixture were studied - angle of repose (°): 34.27±1.78; flow time: 2.2±0.4; HR: 1.05±0.02; compressibility index: 14.27±1.55. Moisture content (%) was found to be 0.27±0.05. The thickness, diameter and hardness values were 3.92±0.05 mm, 11.3±0.06 mm and 81.38±2.27 N, respectively. In uniformity of weight test, the average weight was 404.57±1.6 mg, with less than 5% deviation in 20 randomly selected tablets. Friability value was 0.27% and the disintegration time was found to be less than 15 min. Importantly, dissolution study showed that solubility of ERL was increased by complexation with RAMEB-CD. After 60 minutes, 99% of drug was released from the tablet formulation. These results demonstrate that a new tablet formulation of ERL: RAMEB-CD inclusion complex could be an alternative approach to achieve increased dissolution and oral bioavailability of ERL for NSCLC treatment.

5 July 2021 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
NENAZLI ERDOĞAR
NAZLI ERDOĞAR
SASafiye Akkın
Safiye Akkın
GVGamze Varan
Gamze Varan
EBErem Bilensoy
Erem Bilensoy
The purpose of this study was to investigate the impact of anticancer drug erlotinib-randomly methylated-β-cyclodextrin complex (ERL-RAMEB CD) on drug solubility and dissolution rate. Phase solubility study showed erlotinib displayed maximum solubility in RAMEB CD solution and the stability constant (Kc) was calculated to be 370 ± 16 M−1. The optimal formulation was obtained with ERL-RAMEB CD in a 1:1 molar ratio using the co-lyophilization technique. Differential scanning calorimetry (DSC) and Scanning electron microscopy (SEM) verified the inclusion of complex formation. In vitro dissolution study confirmed ERL-RAMEB CD as a favorable approach to increase drug dissolution with a 1.5-fold increase than free ERL at 1 h. An improved dissolution with ∼88.4% drug release at 1 h was observed, in comparison with Erlotinib with ∼58.7% release in 45 min. The in vitro cytotoxicity results indicated that the ERL-RAMEB CD inclusion complex reduced cell viability than free erlotinib. Caco-2 cell uptake that is indicative of drug intestinal permeability resulted in a 5-fold higher uptake of ERL-RAMEB CD inclusion complex than the ERL solution. Hence, ERL-RAMEB CD complexation displays a strong potential to increase dissolution and permeability of erlotinib leading eventually to enhanced oral bioavailability.